Effect of tetrahydrocannabinol: cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study

被引:8
|
作者
Mallada Frechin, Javier [1 ]
机构
[1] Hosp Gen Elda, Unidad Neurol, Elda, Alicante, Spain
关键词
activities of daily living; multiple sclerosis; spasticity; THC:CBD oromucosal spray;
D O I
10.2217/nmt-2017-0055
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A Summary points Evolution in activities of daily living in patients with moderate to severe multiple sclerosis spasticity receiving add-on tetrahydrocannabinol: cannabidiol (THC: CBD) oromucosal spray was assessed using a 16-item survey. Compared with baseline status before treatment, THC: CBD oromucosal spray produced a general improvement in activities of daily living including a statistically significant improvement in the item 'standing up' (p < 0.05). THC: CBD oromucosal spray also produced statistically significant improvements (p < 0.01) in spasticity severity, number of spasms per day, pain, sleep disorders and bladder dysfunction. Overall, 96.9% of patients provided positive feedback regarding their global impression of change under treatment with THC: CBD oromucosal spray and 78.1% were positive about its overall tolerability. Aim: To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC): cannabidiol (CBD) oromucosal spray. Methods: Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC: CBD oromucosal spray was included to investigate possible recall bias. Results: ADL was maintained or slightly improved with THC: CBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in 'standing up' (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THC: CBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THC: CBD oromucosal spray had a positive global impression of change during treatment. Conclusion: In this pilot study, THC: CBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 50 条
  • [31] A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis
    Francois Bethoux
    Ruth Ann Marrie
    [J]. The Patient - Patient-Centered Outcomes Research, 2016, 9 : 537 - 546
  • [32] Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity
    Conte, Antonella
    Silvan, Carlos Vila
    [J]. NEURODEGENERATIVE DISEASES, 2021, 21 (3-4) : 55 - 62
  • [33] A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis
    Bethoux, Francois
    Marrie, Ruth Ann
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2016, 9 (06): : 537 - 546
  • [34] Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
    Zettl, Uwe K.
    Rommer, Paulus
    Hipp, Petra
    Patejdl, Robert
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (01) : 9 - 30
  • [35] Effect of Applying Progressive Muscle Relaxation Activities of Daily Living in Multiple Sclerosis Patients
    Ghaffari, Somayyeh
    Ahmadi, Fazlollah
    Nabavi, Seyyed Masoud
    Me'marian, Robabeh
    Kazem-Nejad, Anoushirvan
    [J]. ARCHIVES OF REHABILITATION, 2007, 8 (02): : 73 - 80
  • [36] A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis
    Bethoux, Francois A.
    Farrell, Rachel
    Checketts, Daniel
    Sahr, Natasha
    Berwaerts, Joris
    Alexander, Jessica K.
    Skobieranda, Franck
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
  • [37] THC/CBD oromucosal spray in patients with multiple sclerosis bladder dysfunction: a pilot prospective study
    Clerici, V. Torri
    Politi, P. L.
    Mercurio, S.
    Studer, V.
    Brambilla, L.
    Antozzi, C.
    Confalonieri, P.
    Giovannetti, A.
    Tonietti, S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 957 - 958
  • [38] THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study
    Giorgia Teresa Maniscalco
    R. Aponte
    D. Bruzzese
    G. Guarcello
    V. Manzo
    M. Napolitano
    O. Moreggia
    F. Chiariello
    C. Florio
    [J]. Neurological Sciences, 2018, 39 : 97 - 102
  • [39] THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study
    Maniscalco, Giorgia Teresa
    Aponte, R.
    Bruzzese, D.
    Guarcello, G.
    Manzo, V.
    Napolitano, M.
    Moreggia, O.
    Chiariello, F.
    Florio, C.
    [J]. NEUROLOGICAL SCIENCES, 2018, 39 (01) : 97 - 102
  • [40] Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis
    Yahiya Y. Syed
    Kate McKeage
    Lesley J. Scott
    [J]. Drugs, 2014, 74 : 563 - 578